GIBCO Hanks Balanced Salt Solution (HBSS) (1X); liquid from Invitrogen
BLOCK-iT Adenoviral RNAi Expression System from Invitrogen
pCC1BAC/plndigoBAC-5 Reverse Sequencing Primer from EPICENTRE Biotechnologies
...ervices ,,GenScript offers many antibody m...nd antibody fragmentation. Labeling antibodies wit...n and quantitation of the target molecule. In some...binding (Fab) portion of the antibody. For these a...
Biology Products:(Date:11/22/2009)...xposed prenatally to tobacco smoke and during chil...HD, according to research done at Cincinnati Child...ates that up to 35 percent of ADHD cases in childr...y eliminating both of these environmental exposure...n , "Tobacco and lead exposure each have their ...
(Date:11/22/2009)...r 23, 2009 Agios Pharmaceuticals today announced ...t time, that the mutated IDH1 gene has a novel enz..., or oncogene. This breakthrough discovery shows t..., 2-hydroxyglutarate (2HG), which may contribute t...as, the most common type of brain cancers. This di...
(Date:11/20/2009)... all read studies about the health benefits of hav...molecular level, where amino acids known as cystei... than when paired up with other cysteines. , Now... with colleagues in Belgium, have discovered a new.... The research appears in the Nov. 20 issue of the...
Breaking Biology News(10 mins):Exposure to lead, tobacco smoke raises risk of ADHD 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4Saving the single cysteine: New antioxidant system found 2Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 1Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 2Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 1The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 2The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 4The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 5Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 1Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 2Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 3(Date:11/20/2009)...tin American countries have an opportunity to take...archers from the University of Valencia (UV), work...died the productive fabric of the Spanish biotechn...ood and plant sectors have more clout than those i... applied to food and plants has been overlooked by...
(Date:11/20/2009)... SEATTLE, Nov. 20 Cell T...ounced today that the Ninth Circuit Court of Appea...that CTI should be allowed to pursue all of its cl... to the District Court for trial. CTI filed a com...party reimbursement consultant for CTI,s product T...
(Date:11/19/2009)...TTLE, Nov. 19 Omeros Cor...d financial results for the third quarter ended Se...mber 30, 2009, Omeros reported a net loss of $3.9 ...loss of $7.4 million, or $2.54 per share, for the ...tember 30, 2009, the Company reported a net loss o...
(Date:11/19/2009)... MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewsw...sion Resources find that the leading driver of ant...e is broad-spectrum activity against gram-positive...f organisms that can cause nosocomial pneumonia, s...primarily for agents that provide appropriate cove...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3